1-bromo-6,6-difluorohexane | 168268-71-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1-bromo-6,6-difluorohexane
• 英文别名: 6-bromo-1,1-difluorohexane
• CAS: 168268-71-1
• 化学式: C₆H₁₁BrF₂
• 分子量: 201.054
• InChiKey: UCHYRRQGQPHTDC-UHFFFAOYSA-N

物化性质

• 沸点：
  174.1±8.0 °C(Predicted)
• 密度：
  1.322±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-bromo-6,6-difluorohexane 、 (S)-(-)-N-[4-[4-(ethylamino)-1-hydroxybutyl]phenyl]methanesulfonamide 在 碳酸氢钠 作用下， 以 乙腈 为溶剂， 反应 18.0h， 生成 (S)-(-)-N-[4-[4-[(6,6-difluorohexyl)ethylamino]-1-hydroxybutyl]phenyl]methanesulfonamide
  参考文献：
  名称：

  Progress toward the Development of a Safe and Effective Agent for Treating Reentrant Cardiac Arrhythmias:  Synthesis and Evaluation of Ibutilide Analogues with Enhanced Metabolic Stability and Diminished Proarrhythmic Potential

  摘要：

  A series of ibutilide analogues with fluorine substituents on the heptyl side chain was prepared and evaluated for class III antiarrhythmic activity, metabolic stability, and proarrhythmic potential. It was found that fluorine substituents stabilized the side chain to metabolic oxidation. Many of the compounds also retained the ability to increase the refractoriness of cardiac tissue at both slow and fast pacing rates. The potential for producing polymorphic ventricular tachycardia in the rabbit model was dependent on the chirality of the benzylic carbon. The S-enantiomers generally had less proarrhythmic activity than the corresponding racemates. One compound from this series (45E, trecetilide fumarate) had excellent antiarrhythmic activity and metabolic stability and was devoid of proarrhythmic activity in the rabbit model. It was chosen for further development.

  DOI：

  10.1021/jm0004289
• 作为产物：
  描述：

  6-溴正己醇 在 草酰氯 、 二甲基亚砜 、 4,4'-二氨基二苯乙烯-2,2'-二磺酸 作用下， 以 四氯化碳 、 二氯甲烷 为溶剂， 反应 23.5h， 生成 1-bromo-6,6-difluorohexane
  参考文献：
  名称：

  Progress toward the Development of a Safe and Effective Agent for Treating Reentrant Cardiac Arrhythmias:  Synthesis and Evaluation of Ibutilide Analogues with Enhanced Metabolic Stability and Diminished Proarrhythmic Potential

  摘要：

  A series of ibutilide analogues with fluorine substituents on the heptyl side chain was prepared and evaluated for class III antiarrhythmic activity, metabolic stability, and proarrhythmic potential. It was found that fluorine substituents stabilized the side chain to metabolic oxidation. Many of the compounds also retained the ability to increase the refractoriness of cardiac tissue at both slow and fast pacing rates. The potential for producing polymorphic ventricular tachycardia in the rabbit model was dependent on the chirality of the benzylic carbon. The S-enantiomers generally had less proarrhythmic activity than the corresponding racemates. One compound from this series (45E, trecetilide fumarate) had excellent antiarrhythmic activity and metabolic stability and was devoid of proarrhythmic activity in the rabbit model. It was chosen for further development.

  DOI：

  10.1021/jm0004289

文献信息

• Antiarrhythmic methanesulfonamides
  申请人：The Upjohn Company

  公开号：US05405997A1

  公开（公告）日：1995-04-11

  Methanesulfonamides are structurally depicted by Formula I' ##STR1## or its pharmacologically acceptable salts where R.sub.3 is a C.sub.1-7 alkyl substituted with C.sub.3-7 cycloalkyl, or a C.sub.1-10 alkyl substituted with one to eight fluorine atoms, one to three hydroxy, one to three C.sub.1-5 acyloxy or one to three C.sub.1-4 alkoxy substituents. These compounds are useful as Class III antiarrhythmic agents and are stable against rapid metabolism. Methods for treating cardiac arrhythmias with the compounds of Formula I' as well as compositions thereof are also described.

  甲磺酰胺类化合物结构如式I所示：##STR1##或其药理学上可接受的盐，其中R3为被C3-7环烷基取代的C1-7烷基，或被一至八个氟原子、一至三个羟基、一至三个C1-5酰氧基或一至三个C1-4烷氧基取代的C1-10烷基。这些化合物作为III类抗心律失常药物具有用途，并且对快速代谢稳定。还描述了使用式I化合物及其组合物治疗心律失常的方法。
• [EN] COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LA PRÉVENTION ET/OU LE TRAITEMENT D'UNE MALADIE MITOCHONDRIALE, NOTAMMENT L'ATAXIE DE FRIEDREICH
  申请人：STEALTH BIOTHERAPEUTICS CORP

  公开号：WO2021202986A1

  公开（公告）日：2021-10-07

  The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).

  该披露提供了治疗化合物、组合物（例如治疗剂或药物）和方法，用于预防或治疗哺乳动物主体中的线粒体疾病，如弗里德赖希共济失调，减少与线粒体疾病（例如弗里德赖希共济失调）相关的风险因素、症状和/或症状，并/或减少线粒体疾病（例如弗里德赖希共济失调）的发生可能性或严重程度。该披露还提供了用于生产上述治疗组合物的新型中间体。在某些情况下，这些中间体本身可能是治疗剂或治疗剂的前药（例如治疗化合物的还原形式）。
• Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof
  申请人：Patoiseau Jean-Francois

  公开号：US20060135785A1

  公开（公告）日：2006-06-22

  The present invention relates to novel analide derivatives of formula I, enantiomers and stereoisomers thereof, and their pharmaceutically acceptable salts. The invention also relates to pharmaceutical compositions containing the compounds and methods of treating hypercholesterolemia and atherosclerosis therewith.

  本发明涉及公式I的新型阿那利德衍生物，其对映体和立体异构体，以及其药用可接受的盐。该发明还涉及含有这些化合物的药物组合物以及用于治疗高胆固醇血症和动脉粥样硬化的方法。
• DERIVES D'ALPHA-PHENYL ACETANILIDES PRESENTANT UNE ACTIVITE INHIBITRICE DE L'ACAT ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP1558590A1

  公开（公告）日：2005-08-03
• COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA
  申请人：Stealth BioTherapeutics Corp

  公开号：US20210317146A1

  公开（公告）日：2021-10-14

  The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).